Compare GOOS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOOS | VOR |
|---|---|---|
| Founded | 1957 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 931.6M | 813.3M |
| IPO Year | 2016 | 2021 |
| Metric | GOOS | VOR |
|---|---|---|
| Price | $9.84 | $18.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $12.60 | ★ $45.33 |
| AVG Volume (30 Days) | 518.6K | ★ 1.8M |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $5.16 | N/A |
| P/E Ratio | $75.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.17 | $1.62 |
| 52 Week High | $15.43 | $49.95 |
| Indicator | GOOS | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 54.88 |
| Support Level | $9.25 | $11.62 |
| Resistance Level | $10.42 | $19.70 |
| Average True Range (ATR) | 0.26 | 1.68 |
| MACD | 0.06 | -0.21 |
| Stochastic Oscillator | 76.87 | 35.87 |
Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale; Direct to Consumer (DTC), and Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia-Pacific, and Europe, the Middle East, and Africa.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.